Arcellx CFO Sells 11,219 Shares at $113.82 as P/E Dives to -29.5
Arcellx shows negative P/E of -29.54 and P/S of 183.24 alongside a current ratio of 3.99, highlighting unprofitability despite solid liquidity and high growth expectations. CFO Michelle sold 11,219 shares at $113.82 Feb. 25, cutting holdings to 33,938 shares, while Gilead Sciences’ $115 per-share offer values Arcellx at $7.8 billion.
1. CFO Executes Major Share Sale
On Feb. 25, CFO Michelle disposed of 11,219 shares at $113.82 each, reducing her stake to 33,938 shares and signaling potential insider sentiment as the company remains unprofitable.
2. Negative Profitability and High Valuation
Arcellx reports a P/E ratio of -29.54 and a P/S ratio of 183.24, underscoring a market willing to pay premiums for future growth despite ongoing losses and a negative earnings yield of -3.38%.
3. Strong Liquidity Despite Cash Burn
The company maintains a current ratio of 3.99, reflecting robust short-term liquidity, even as it reports a negative enterprise value to operating cash flow ratio of -33.07, indicating cash burn challenges.
4. Acquisition Offer Frames Market Expectations
Gilead Sciences’ $115 per-share bid values Arcellx at $7.8 billion, setting a high benchmark that contrasts with the stock’s bearish trend below its 20-day and 100-day moving averages.